(Q24814420)

English

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 July 2017

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort (English)

1 reference

Europe PubMed Central

4 July 2017

0 references

anti-retroviral agent

0 references

0 references

1

0 references

Nicoletta Ladisa

9

0 references

Giampiero Carosi

17

0 references

Eugenia Quiros-Roldan

6

0 references

Giuseppe Lapadula

2

0 references

Giovanni Sotgiu

object named as

Giovanni Sotgiu

11

0 references

Carmine Tinelli

object named as

Carmine Tinelli

16

0 references

4

object named as

Massimo Puoti

1 reference

Europe PubMed Central

4 July 2017

15

object named as

Gaetano Filice

1 reference

Europe PubMed Central

4 July 2017

author name string

Salvatore Casari

3

1 reference

Europe PubMed Central

4 July 2017

Mark Nelson

5

1 reference

Europe PubMed Central

4 July 2017

Daniele Bella

7

1 reference

Europe PubMed Central

4 July 2017

Giuseppe Pastore

8

1 reference

Europe PubMed Central

4 July 2017

Lorenzo Minoli

10

1 reference

Europe PubMed Central

4 July 2017

Francesco Mazzotta

12

1 reference

Europe PubMed Central

4 July 2017

Sergio Lo Caputo

13

1 reference

Europe PubMed Central

4 July 2017

Giovanni Di Perri

14

1 reference

Europe PubMed Central

4 July 2017

EPOKA-MASTER Study Group

18

1 reference

Europe PubMed Central

4 July 2017

language of work or name

0 references

publication date

14 July 2005

1 reference

Europe PubMed Central

4 July 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

4 July 2017

5

1 reference

Europe PubMed Central

4 July 2017

1

0 references

58

1 reference

Europe PubMed Central

4 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2334-5-58

0 references

Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1188059

28 September 2017

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1188059

28 September 2017

Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1188059

28 September 2017

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1188059

28 September 2017

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1188059

30 May 2018

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-58

21 January 2018

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-58

21 January 2018

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-58

21 January 2018

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-58

21 January 2018

Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-58

21 January 2018

Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAART

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-5-58

21 January 2018

Hepatotoxicity after introduction of highly active antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16018804

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-5-58

1 reference

Europe PubMed Central

4 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 July 2017

1 reference

Europe PubMed Central

4 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24814420&oldid=1879119166"